晚期非小细胞肺癌化疗前后的血清AGR2水平变化及临床意义

摘要

目的 探讨晚期非小细胞肺癌(NSCLC)患者化疗前后血清前梯度蛋白2(AGR2)水平变化及其对预后的影响.方法 选取本院2013年6月至2015年9月收治的35例NSCLC患者为实验组,接受吉西他滨联合顺铂方案化疗;选取20例健康人群为正常对照组.采用ELISA法分别检测肺癌组化疗前后及正常对照组的血清AGR2水平,分析血清AGR2水平与NSCLC临床病理特征及预后的关系.结果 实验组化疗前的血清AGR2水平为(15.63±5.20)ng/ml,高于正常对照组的(3.65±1.38)ng/ml,差异有统计学意义(P<0.01);实验组化疗后血清AGR2水平为(8.56±2.66)ng/ml,低于化疗前水平(P<0.01);NSCLC患者化疗前后的血清AGR2水平与肿瘤直径、临床分期有关(P<0.05);Cox比例风险回归模型分析显示,化疗前血清AGR2水平是影响患者生存期的独立危险因素.结论 血清AGR2水平在评估NSCLC患者的化疗疗效及预后有着潜在的临床价值.%Objective To investigate the changes of serum anterior gradient-2 ( AGR2) in patients with advanced non-small cell lung cancer ( NSCLC) before and after chemotherapy and the relationship of it with prognosis. Methods From June 2013 to Sep-tember 2015, 35 patients with NSCLC were treated with gemcitabine and cisplatin regimen ( treatment group) . Meanwhile, 20 healthy volunteers were enrolled as control group. The level of serum AGR2 was detected by ELISA in treatment group before and after chemo-therapy and control group. The relationship of serum AGR2 with prognosis and clinical pathologic features was analyzed. Results The level of serum AGR2 before chemotherapy in treatment group was (15. 63±5. 20) ng/ml, higher than (3. 65±1. 38) ng/ml in control group (P<0. 01). Serum level of AGR2 after chemotherapy was (8. 56±2. 66) ng/ml, significantly lower than the level before chemo-therapy in NSCLC patients ( P<0. 01) . The serum levels of AGR2 in NSCLC patients before and after chemotherapy were closely relat-ed to tumor size and clinical stages ( P<0. 05) . Cox proportional hazards regression models showed that the level of serum AGR2 before chemotherapy was an independent factor of influencing the survival time. Conclusion The level of serum AGR2 may have potential clinical value to assess the therapeutic efficacy of chemotherapy and prognosis in patients of NSCLC.